Literature DB >> 23934052

[Urological comorbidities in patients with rheumatoid arthritis : literature review].

A Friedl1, M Mustak, W Höltl, L Erlacher.   

Abstract

Patients with rheumatoid arthritis (RA) have an increased risk of urolithiasis which is further negatively impacted by a reduced bone density. Interstitial cystitis also tends to occur more often in patients with rheumatic diseases. The high incidence of bacterial urogenital infections is influenced by the use of immunomodulating drugs. Many RA patients have to undergo numerous tests until a diagnosis is reached and are then treated as outpatients on a tightly controlled schedule. Despite a closely controlled rheumatological follow-up, urological screening and determination of a baseline prostate-specific antigen (PSA) value (in men over 45 years old) should not be neglected. In patients with an increased risk of renal and bladder neoplasms or when such a diagnosis is known, the benefit of long-term use of high doses of non-steroidal anti-inflammatory drugs (NSAID, aspirin type) should be carefully weighed up with a risk profile and after specialist urological assessment. Patients who suffer from sexual dysfunction due to physical limitations and prolonged medical therapy should undergo urological and gynecological assessment to exclude contributing causes. The use of aphrodisiacs and erection-enhancing drugs (e.g. PDE5 inhibitors, local injection with prostaglandins and vacuum therapy) require prior approval by a medical specialist and also cardiovascular stability. Acute urinary retention is more common in chronic inflammatory musculoskeletal diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23934052     DOI: 10.1007/s00393-013-1231-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  38 in total

Review 1.  Kidney stones: pathophysiology and medical management.

Authors:  Orson W Moe
Journal:  Lancet       Date:  2006-01-28       Impact factor: 79.321

Review 2.  [Etiopathology, risk factors, environmental influences and epidemiology of bladder cancer].

Authors:  T Kälble
Journal:  Urologe A       Date:  2001-11       Impact factor: 0.639

3.  Bone mineral density and urolithiasis interaction in rheumatoid arthritis.

Authors:  Nurgül Arinci Incel; Nazmi Incel; Bariş Nacir
Journal:  J Bone Miner Metab       Date:  2004       Impact factor: 2.626

4.  Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis.

Authors:  Paul Hong; Janet E Pope; Janine M Ouimet; Eugenia Rullan; James R Seibold
Journal:  J Rheumatol       Date:  2004-03       Impact factor: 4.666

5.  Sexual dysfunction among patients with arthritis.

Authors:  D J Blake; R Maisiak; A Koplan; G S Alarcón; S Brown
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

Review 6.  Overview summary statement. Diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

Authors:  Anthony J Schaeffer; Nand S Datta; Jackson E Fowler; John N Krieger; Mark S Litwin; Robert B Nadler; J Curtis Nickel; Michel A Pontari; Daniel A Shoskes; Scott I Zeitlin; Carol Hart
Journal:  Urology       Date:  2002-12       Impact factor: 2.649

7.  Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases.

Authors:  Michael Mahler; Todd Parker; Carol L Peebles; Luis E Andrade; Andreas Swart; Yvette Carbone; David J Ferguson; Danilo Villalta; Nicola Bizzaro; John G Hanly; Marvin J Fritzler
Journal:  J Rheumatol       Date:  2012-09-01       Impact factor: 4.666

8.  Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population.

Authors:  Louise K Mercer; Rebecca Davies; James B Galloway; Audrey Low; Mark Lunt; William G Dixon; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2013-01       Impact factor: 7.580

9.  Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?

Authors:  Karina I Halilova; Elizabeth E Brown; Sarah L Morgan; S Louis Bridges; Min-Ho Hwang; Donna K Arnett; Maria I Danila
Journal:  Int J Rheumatol       Date:  2012-07-09

10.  Rheumatoid arthritis and sexuality: a patient survey in France.

Authors:  Gisela Kobelt; Brigitte Texier-Richard; Sylvain Mimoun; Anne-Sophie Woronoff; David-Romain Bertholon; Aleth Perdriger; Yves Maugars; Bernard Combe
Journal:  BMC Musculoskelet Disord       Date:  2012-09-10       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.